Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 97, Issue 1, Pages 99-118Publisher
WILEY
DOI: 10.1002/ajh.26379
Keywords
-
Categories
Ask authors/readers for more resources
For multiple myeloma patients refractory to current therapies, CAR T-lymphocytes, bsAbs, and ADCs show potential with ide cel and belamaf approved in the relapsed/refractory setting. bsAbs demonstrate promising quick and deep responses in clinical trials.
Patients with multiple myeloma who are refractory to currently available effective therapies have short expected survival. Modalities harvesting the knowledge of the immune characteristics and microenvironment of myeloma such as chimeric antigen receptor (CAR) T-lymphocytes, bispecific antibodies (bsAbs), and antibody-drug conjugates (ADCs) have shown potential in early phase trials. Based on data from phase 2 studies, idecabtagene vicleucel (ide cel), an anti-B-cell maturation antigen CAR T-product and belantamab mafodotin (belamaf), an ADC are currently approved in the relapsed/refractory setting. bsAbs have shown promise with quick and deep responses. In this review, we summarize the available evidence on these treatments from clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available